$8.50
0.050.59%
At close: -
$8.63
0.131.53%
After Hours: Dec 20, 4:33 PM EDT
Comments
Loading...
Ocular Therapeutix (OCUL) Forecast
NewsEarningsOcular Therapeutix (OCUL) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestOcular Therapeutix (NASDAQ:OCUL) Stock Quotes, Forecast and News Summary
Ocular Therapeutix Stock (NASDAQ: OCUL) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Ocular Therapeutix (OCUL) stock?
You can purchase shares of Ocular Therapeutix (NASDAQ:OCUL) through any online brokerage.
Who are Ocular Therapeutix (OCUL) competitors?
Other companies in Ocular Therapeutix’s space includes: WAVE Life Sciences (NASDAQ:WVE), Supernus Pharmaceuticals (NASDAQ:SUPN), Tarsus Pharmaceuticals (NASDAQ:TARS), Phibro Animal Health (NASDAQ:PAHC) and Neumora Therapeutics (NASDAQ:NMRA).
What is the forecast, or price target, for Ocular Therapeutix (OCUL) stock?
Ocular Therapeutix has a consensus price target of $16.22.
What is the current price for Ocular Therapeutix (OCUL)?
The stock price for Ocular Therapeutix (NASDAQ: OCUL) is $8.63 last updated December 20, 2024 at 4:33 PM EST.
Does Ocular Therapeutix (OCUL) pay a dividend?
There are no upcoming dividends for Ocular Therapeutix.
When is Ocular Therapeutix (NASDAQ:OCUL) reporting earnings?
Ocular Therapeutix’s Q4 earnings are confirmed for Monday, March 10, 2025.
Is Ocular Therapeutix (OCUL) going to split?
There is no upcoming split for Ocular Therapeutix.
What sector and industry does Ocular Therapeutix (OCUL) operate in?
Ocular Therapeutix is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.